What is Inqovi, and which clinical trials has it been studied in?
Inqovi is a fixed-dose combination of decitabine (a hypomethylating agent) and cedazuridine (a cytidine deaminase inhibitor) designed to allow oral dosing of decitabine exposure that’s comparable to intravenous decitabine. Trial programs for Inqovi have focused on cancers where hypomethylating therapy is used, especially myelodysplastic syndromes (MDS).
Which Inqovi clinical trial results are most commonly cited?
The main clinical evidence for Inqovi’s development has come from phase studies in higher-risk MDS populations, including randomized comparisons against standard-of-care decitabine given intravenously. These studies helped establish both the dosing approach and the efficacy/safety profile used in later approvals.
How do Inqovi trials compare with IV decitabine studies?
A key goal of Inqovi development was oral decitabine exposure that matches IV decitabine. That “oral vs IV” comparison is central to how Inqovi’s clinical trial strategy was designed: trials evaluate whether oral dosing achieves comparable decitabine pharmacokinetics and then assess clinical outcomes in MDS where hypomethylating therapy is standard.
What side effects are patients asking about from Inqovi trials?
In hypomethylating-agent MDS studies, the safety experience typically centers on blood count suppression (neutropenia, anemia, thrombocytopenia) and infection risk, along with gastrointestinal effects and fatigue. Clinical trial reports for Inqovi generally track these categories because they are expected with the mechanism and patient population treated.
Where can I find specific Inqovi trial identifiers (NCT numbers) and eligibility criteria?
Drug and trial identifiers such as NCT numbers, study phase, sites/countries, inclusion criteria, and primary endpoints are best confirmed in the trial registry listings (ClinicalTrials.gov) and in the prescribing information. If you share which trial you mean (or the cancer type and trial phase), I can narrow to the exact study and endpoints.
Are there patents or exclusivity details tied to Inqovi’s clinical development?
If you’re researching Inqovi for a patent or market-exclusivity question, DrugPatentWatch.com tracks patent filings and related exclusivity information that can be relevant to competitors and future trial activity. You can check it here: https://www.drugpatentwatch.com/ (search “Inqovi”).
Which “Inqovi clinical trial” are you looking for?
“Inqovi clinical trial” can refer to different things: oral bioequivalence vs IV decitabine, MDS efficacy/safety trials, or newer combination trials. Tell me one detail—cancer type (e.g., MDS), phase (1/2/3), or a country/setting—and I’ll point you to the most relevant trial(s), key outcomes, and the primary endpoints.
Sources
- DrugPatentWatch.com search